A type of cancer treatment used to boost the body's immune system may worsen inflammation in the arteries that distribute blood from the heart, according to a small study.
Sep 8, 2020
0
25
The National Institute for Health and Care Excellence (NICE) has recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma on the NHS in England.
Aug 21, 2020
0
1
A study has found strong similarities between children withendemic Burkitt lymphoma—an aggressive cancer that attacks the body's defense system and children with silent malaria infection.
Aug 11, 2020
0
0
Prognosis describes how serious a patient's cancer is and his or her chance of survival. A genetic biomarker is a clinically useful tool to help estimate the state of the disease. A study, conducted by the Faculty of Medicine ...
Aug 4, 2020
0
1
Researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) and The Ohio State University Wexner Medical Center are conducting ...
Jul 29, 2020
0
3
Today's Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for mantle cell lymphoma (MCL) represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber ...
Jul 24, 2020
0
3
A team of researchers investigating how a certain type of drugs can kill cells has discovered that these drugs can do more harm than good when used in combination with other cancer treatments.
Jul 24, 2020
0
2
CAR-T cell therapy, which attacks cancer cells using a person's reprogrammed immune cells, has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical ...
Jul 23, 2020
0
3
A general problem encountered in cancer therapy is that many patients develop resistance to a drug over the course of treatment. In the case of the blood cancer anaplastic large cell lymphoma (ALCL), an international team ...
Jul 15, 2020
0
0
A research team led by Hong Kong Baptist University (HKBU) has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the shrinkage of tumors caused by ...
May 11, 2020
0
8
